Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease
-
By
-
Kuo Fang
-
Ji Miao
-
Guobin Song
-
June 5, 2026
-
Clinical Scorecard: Role of Insulin-like Growth Factor Binding Proteins in Metabolic Dysfunction-Related Steatotic Liver Disease
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Involvement of insulin-like growth factor binding proteins (IGFBPs) in hepatic metabolism, inflammation, and fibrotic remodeling. |
| Target Population | |
| Care Setting | |
Key Highlights
- MASLD progresses from hepatic steatosis to steatohepatitis, fibrosis, and cirrhosis.
- IGFBP1 and IGFBP2 promote lipid oxidation and increase insulin sensitivity.
- IGFBP3 and IGFBP5 have dual roles in restraining lipogenesis and promoting hepatocellular injury.
- IGFBP7 impairs insulin signaling and drives fibrosis.
Guideline-Based Recommendations
Diagnosis
- Consider metabolic syndrome factors in the assessment of MASLD.
Management
- Focus on metabolic interventions to address insulin resistance and obesity.
Monitoring & Follow-up
- Evaluate IGFBP levels as potential biomarkers for disease progression.
Risks
- Progression to cirrhosis and hepatocellular carcinoma (HCC) if left unmanaged.
Patient & Prescribing Data
Patients with metabolic dysfunction and liver disease.
Limited therapeutic options currently available for MASLD.
Clinical Best Practices
Related Resources & Content
